Protara Therapeutics, Inc. TARA 深 滬
已收盤 02-06 16:00:00 美东时间
6.65
+0.150
+2.31%
華盛通- 最 高6.89
- 今 開6.66
- 成交量 61.52万股
- 最 低 6.60
- 昨 收 6.50
- 總市值 3.56亿
- 52周最高 7.82
- 市盈率 靜 --
- 換手率 1.15%
- 52周最低 2.77
- 委 比 86.00%
- 總股本 5358.73万
- 歷史最高 800.00
- 量 比 0.85
- 振 幅 4.46%
- 歷史最低 1.04
- 每 手 1
- 風險率 1.21%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Protara Therapeutics Grants Stock Options and RSUs to New Employee
Protara Therapeutics Grants Stock Options and RSUs to New Employee Protara Therapeutics Inc. has granted inducement non-qualified stock options and restricted stock units (RSUs) to a newly hired employee. The employee received 10,200 stock options with an exercise price of $7.04 per share, the closi
02-03 05:06
Protara Therapeutics gewährt neuem Mitarbeiter Aktienoptionen und RSUs als Vergütungsanreiz
Protara Therapeutics gewährt neuem Mitarbeiter Aktienoptionen und RSUs als Vergütungsanreiz Protara Therapeutics Inc. hat am 2. Februar 2026 die Gewährung von insgesamt 10.200 Aktienoptionen und 5.100 Restricted Stock Units (RSUs) an einen neu eingestellten Mitarbeiter bekannt gegeben. Die Aktienopt
02-03 05:06
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Prototherapeutics授予1名新员工总计10,200股期权和5,100个RSU。期权行权价为7.04美元，行权期4年；RSU将在4月1日授予，分三年行权。公司致力于开发针对癌症和罕见病的创新疗法。
02-02 21:05
Protara Therapeutics To Feature Interim Data From Cohort Of BCG-Unresponsive NMIBC Patients In Ongoing Phase 2 ADVANCED-2 Trial Of TARA-002 At Upcoming ASCO GU
Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that updated interim data from the cohort of
01-22 21:03
Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium
Protara Therapeutics announced that updated interim data from the BCG-Unresponsive NMIBC cohort in the Phase 2 ADVANCED-2 trial of TARA-002 will be presented at the ASCO GU Cancers Symposium in February 2026. The presentation will include safety and efficacy data from approximately 25 evaluable patients. TARA-002 is an investigational cell therapy being developed for NMIBC and lymphatic malformations, with a mechanism of action targeting immune p...
01-22 13:00
美股大行评级 | 瑞银上调美光科技目标价从300美元升至400美元；Freedom上调百度目标价从120美元升至160美元
今日重点评级关注：Needham：维持Vaxcyte"买入"评级，目标价从90美元升至110美元；Citizens: 维持LGI Homes"跑赢大市"评级，目标价从85美元升至95美元
01-08 18:33
Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Protara Therapeutics, Inc. announced that its management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 3:45 pm PT in San Francisco. The presentation will discuss the company's transformative therapies for cancer and rare diseases, including its lead candidate TARA-002 for non-muscle invasive bladder cancer and lymphatic malformations, as well as IV Choline Chloride for patients on parenteral nutrition. ...
01-07 13:00
Protara, CeriBell rise on FDA breakthrough designations
Protara Therapeutics (TARA) and CeriBell (CBLL) were among the notable healthcare gainers on Monday after the FDA issued breakthrough designations for their experimental products, TARA-002 cell-based ...
01-06 00:00
Protara Therapeutics' TARA-002 Gets FDA's Breakthrough Therapy, Fast Track Designations To Treat Macrocystic, Mixed Cystic Lymphatic Malformations
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has
01-05 21:15
Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations
Protara Therapeutics' TARA-002, an investigational cell-based therapy, has been granted Breakthrough Therapy and Fast Track designations by the FDA for treating pediatric patients with lymphatic malformations (LMs). Additionally, TARA-002 has been selected for the FDA's CMC Development and Readiness Pilot Program, aimed at accelerating manufacturing and clinical development. Protara plans to meet with the FDA to define the path to registration an...
01-05 13:00
